Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 5.
doi: 10.1515/dmdi-2020-0173. Online ahead of print.

Drugs intervention study in COVID-19 management

Muhammad Taher  1 , Noratika Tik  1 , Deny Susanti  2
Affiliations
Review

Drugs intervention study in COVID-19 management

Muhammad Taher et al. Drug Metab Pers Ther. .

Abstract

By 9 February 2021, the Coronavirus has killed 2,336,650 people worldwide and it has been predicted that this number continues to increase in year 2021. The study aimed to identify therapeutic approaches and drugs that can potentially be used as interventions in Coronavirus 2019 (COVID-19) management. A systematic scoping review was conducted. Articles reporting clinical evidence of therapeutic management of COVID-19 were selected from three different research databases (Google Scholar, PubMed, and Science Direct). From the database search, 31 articles were selected based on the study inclusion and exclusion criteria. This review paper showed that remdesivir and ivermectin significantly reduced viral ribonucleic acid (RNA) activity. On the other hand, convalescent plasma (CP) significantly improved COVID-19 clinical symptoms. Additionally, the use of corticosteroid increased survival rates in COVID-19 patients with acute respiratory distress syndrome (ARDS). Findings also indicated that both hydroxychloroquine and favipiravir were effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, lopinavir-ritonavir combination was not effective against COVID-19. Finally, ribavirin, galidesivir, and sofosbuvir showed potential therapeutic benefit in treating COVID-19, but there is a lack of clinical evidence on their effectiveness against SARS-CoV-2. Remdesivir, ivermectin, favipiravir, hydroxychloroquine, dexamethasone, methylprednisolone, and CP are the therapeutic agents that can potentially be used in COVID-19 management.

Keywords: COVID-19; SARS-CoV-2; antiviral; clinical trial; drug intervention.

PubMed Disclaimer

References

    1. Harapan, H, Itoh, N, Yufika, A, Winardi, W, Keam, S, Te, H, et al.. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health 2020;13:667–73. https://doi.org/10.1016/j.jiph.2020.03.019.
    1. Daga, MK. From SARS-CoV to coronavirus disease 2019 (COVID-19) – a brief review. J Adv Res Med 2020;06:1–9. https://doi.org/10.24321/2349.7181.201917.
    1. Zhang, L, Shen, FM, Chen, F, Lin, Z. Origin and evolution of the 2019 novel coronavirus. Clin Infect Dis 2020;71:882–3. https://doi.org/10.1093/cid/ciaa112.
    1. Su, S, Wong, G, Shi, W, Liu, J, Lai, ACK, Zhou, J, et al.. Epidemiology, genetic recombination and pathogenesis of coronaviruses. Trends Microbiol 2020;24:490–502. https://doi.org/10.1016/j.tim.2016.03.003.
    1. Ruiz, SI, Zumbrun, EE, Nalca, A. Animal models of human viral diseases. In: Conn, PM, editor. Animal models for the study of human disease, 2nd ed. Elsevier Inc; 2017:853–901 pp. https://doi.org/10.1016/B978-0-12-809468-6.00033-4.

LinkOut - more resources